Maia Biotechnology Inc (MAIA) Actualités

MAIA Biotechnology to Present at Biotech Showcase 2025

CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the...

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab MAIA Biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next stage of trial to further assess efficacy of THIO in third line...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form D - Notice of Exempt Offering of Securities